Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1084

Similar articles for PubMed (Select 17086470)

1.

Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.

Majumdar SR, Johnson JA, Lier DA, Russell AS, Hanley DA, Blitz S, Steiner IP, Maksymowych WP, Morrish DW, Holroyd BR, Rowe BH.

Osteoporos Int. 2007 Mar;18(3):261-70. Epub 2006 Nov 4.

PMID:
17086470
2.

A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture.

Majumdar SR, Rowe BH, Folk D, Johnson JA, Holroyd BH, Morrish DW, Maksymowych WP, Steiner IP, Harley CH, Wirzba BJ, Hanley DA, Blitz S, Russell AS.

Ann Intern Med. 2004 Sep 7;141(5):366-73.

PMID:
15353428
3.

Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.

Majumdar SR, Lier DA, Rowe BH, Russell AS, McAlister FA, Maksymowych WP, Hanley DA, Morrish DW, Johnson JA.

Osteoporos Int. 2011 Jun;22(6):1799-808. doi: 10.1007/s00198-010-1412-1. Epub 2010 Sep 29.

PMID:
20878389
4.

Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial.

Majumdar SR, Johnson JA, McAlister FA, Bellerose D, Russell AS, Hanley DA, Morrish DW, Maksymowych WP, Rowe BH.

CMAJ. 2008 Feb 26;178(5):569-75. doi: 10.1503/cmaj.070981.

5.

Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study.

Majumdar SR, Johnson JA, Bellerose D, McAlister FA, Russell AS, Hanley DA, Garg S, Lier DA, Maksymowych WP, Morrish DW, Rowe BH.

Osteoporos Int. 2011 Jan;22(1):223-30. doi: 10.1007/s00198-010-1212-7. Epub 2010 Apr 1.

PMID:
20358359
6.

A multifaceted intervention to improve treatment of osteoporosis in postmenopausal women with wrist fractures: a cluster randomized trial.

Cranney A, Lam M, Ruhland L, Brison R, Godwin M, Harrison MM, Harrison MB, Anastassiades T, Grimshaw JM, Graham ID.

Osteoporos Int. 2008 Dec;19(12):1733-40. doi: 10.1007/s00198-008-0669-0. Epub 2008 Jul 16.

PMID:
18629567
7.

Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial.

Majumdar SR, Lier DA, Beaupre LA, Hanley DA, Maksymowych WP, Juby AG, Bell NR, Morrish DW.

Arch Intern Med. 2009 Jan 12;169(1):25-31. doi: 10.1001/archinte.169.1.25.

PMID:
19139320
8.

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH.

Pharmacoeconomics. 2008;26(4):311-28.

PMID:
18370566
9.

Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial.

Majumdar SR, Beaupre LA, Harley CH, Hanley DA, Lier DA, Juby AG, Maksymowych WP, Cinats JG, Bell NR, Morrish DW.

Arch Intern Med. 2007 Oct 22;167(19):2110-5.

PMID:
17954806
10.

Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures.

Majumdar SR, Lier DA, McAlister FA, Rowe BH, Siminoski K, Hanley DA, Russell AS, Johnson JA.

Am J Med. 2013 Feb;126(2):169.e9-17. doi: 10.1016/j.amjmed.2012.10.009.

PMID:
23331449
11.

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.

Borgström F, Jönsson B, Ström O, Kanis JA.

Osteoporos Int. 2006 Dec;17(12):1781-93. Epub 2006 Sep 29.

PMID:
17009083
12.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
13.

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group.

Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28. Erratum in: Osteoporos Int. 2009 Mar;20(3):499-502.

PMID:
18751937
14.

Facilitated bone mineral density testing versus hospital-based case management to improve osteoporosis treatment for hip fracture patients: additional results from a randomized trial.

Morrish DW, Beaupre LA, Bell NR, Cinats JG, Hanley DA, Harley CH, Juby AG, Lier DA, Maksymowych WP, Majumdar SR.

Arthritis Rheum. 2009 Feb 15;61(2):209-15. doi: 10.1002/art.24097.

15.
16.

Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

Berto P, Maggi S, Noale M, Lopatriello S.

Aging Clin Exp Res. 2010 Apr;22(2):179-88. doi: 10.3275/6816. Epub 2010 Feb 9.

PMID:
20145427
17.

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.

Schwenkglenks M, Lippuner K.

Osteoporos Int. 2007 Nov;18(11):1481-91. Epub 2007 May 26.

PMID:
17530156
18.
19.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
20.

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.

Mueller D, Gandjour A.

Appl Health Econ Health Policy. 2008;6(2-3):113-35. doi: 10.2165/00148365-200806020-00004.

PMID:
19231905
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk